Retension Pharmaceuticals, Inc. Form 8-K — Nov 18, 2026
Retension Pharmaceuticals reported a Q3 2026 net loss of $5.9 million (EPS -$7.33), widened from $1.5 million a year ago, driven by Phase 2b clinical trial costs as R&D spend rose to $5.0 million from $1.4 million. The clinical-stage biotech has no revenue. The company completed an upsized IPO in October 2026, selling 4,312,500 shares at $12.00 per share for $51.75 million in gross proceeds and roughly $45.1 million net. Pro forma cash stands at approximately $54.3 million, funding the ongoing Phase 2b trial of lead candidate RTN-001 in about 280 patients with uncontrolled hypertension.
Key figures
- Cash Position
- 9190083
- Ipo shares
- 4312500
- Total assets
- 14148496
- Greenshoe shares
- 562500
- Ipo net proceeds
- 45100000
- Phase2b patients
- 280
- Total liabilities
- 6658829
- Ipo gross proceeds
- 51750000
- Q3 2025 ga expense
- 299574
- Q3 2025 rd expense
- 1365256
- Q3 2026 ga expense
- 990759
- Q3 2026 rd expense
- 5016602
- Ipo price per share
- 12
- Pro forma cash incl ipo
- 54300000
- Rtm 001 subjects studied
- 265
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.